KORU Medical Systems Reports 22% Revenue Growth, Narrows Q1 Net Loss to $0.8M
summarizeSummary
KORU Medical Systems reported strong Q1 2026 results, with net revenues increasing 22.1% year-over-year to $11.8 million. The company significantly narrowed its net loss to $0.8 million, down from $1.16 million in the prior year, and achieved near breakeven adjusted EBITDA. These results demonstrate continued momentum, building on the strong 22.2% revenue growth and significant net loss reduction reported in the 2025 10-K. The sustained high revenue growth and improved profitability metrics indicate positive operational execution and progress towards financial health, which is material for a company of this size. Investors will monitor the progress of the 510(k) application for the Freedom Infusion System and the advancement of pharmaceutical collaborations into Phase III clinical trials, as these represent future growth catalysts. The reiteration of full-year guidance also suggests management confidence.
At the time of this announcement, KRMD was trading at $3.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.4M. The 52-week trading range was $2.63 to $6.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.